Cancer Stem Cell Hypothesis 2.0 in Glioblastoma: Where Are We Now and Where Are We Going?

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2024 Feb 23

PMID 38394444

Authors

Anthony R Sloan

Daniel J Silver

Sam Kint

Marco Gallo

Justin D Lathia

Affiliations

Soon will be listed here.

Abstract

Over the past 2 decades, the cancer stem cell (CSC) hypothesis has provided insight into many malignant tumors, including glioblastoma (GBM). Cancer stem cells have been identified in patient-derived tumors and in some mouse models, allowing for a deeper understanding of cellular and molecular mechanisms underlying GBM growth and therapeutic resistance. The CSC hypothesis has been the cornerstone of cellular heterogeneity, providing a conceptual and technical framework to explain this longstanding phenotype in GBM. This hypothesis has evolved to fit recent insights into how cellular plasticity drives tumor growth to suggest that CSCs do not represent a distinct population but rather a cellular state with substantial plasticity that can be achieved by non-CSCs under specific conditions. This has further been reinforced by advances in genomics, including single-cell approaches, that have used the CSC hypothesis to identify multiple putative CSC states with unique properties, including specific developmental and metabolic programs. In this review, we provide a historical perspective on the CSC hypothesis and its recent evolution, with a focus on key functional phenotypes, and provide an update on the definition for its use in future genomic studies.

Citing Articles

Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies.

Lv M, Huang Y, Chen Y, Ding K Exp Hematol Oncol. 2025; 14(1):32.

PMID: 40057816 PMC: 11889934. DOI: 10.1186/s40164-025-00622-x.

miR-217-5p NanomiRs Inhibit Glioblastoma Growth and Enhance Effects of Ionizing Radiation via EZH2 Inhibition and Epigenetic Reprogramming.

Korleski J, Sudhir S, Rui Y, Caputo C, Sall S, Johnson A Cancers (Basel). 2025; 17(1).

PMID: 39796709 PMC: 11719642. DOI: 10.3390/cancers17010080.

QSOX1 Modulates Glioblastoma Cell Proliferation and Migration In Vitro and Invasion In Vivo.

Dutt R, Thorpe C, Galileo D Cancers (Basel). 2024; 16(21).

PMID: 39518060 PMC: 11545231. DOI: 10.3390/cancers16213620.

Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.

Brem S Brain Behav Immun Health. 2024; 42:100859.

PMID: 39512605 PMC: 11541944. DOI: 10.1016/j.bbih.2024.100859.

ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells.

Zhu H, Cheng L, Liu D, Ma X, Chen Z, Fan H Neuro Oncol. 2024; 27(3):695-710.

PMID: 39447031 PMC: 11889726. DOI: 10.1093/neuonc/noae224.

References

Eaves C, Pera M . Cancer Stem Cells: Notes for Authors. Stem Cell Reports. 2020; 14(2):167-168. PMC: 7013247. DOI: 10.1016/j.stemcr.2020.01.011. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Patel A, Tirosh I, Trombetta J, Shalek A, Gillespie S, Wakimoto H . Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396-401. PMC: 4123637. DOI: 10.1126/science.1254257. View

Huang Y, Chang K, Li C, Lieu A, Lin C . AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling Pathways. Curr Issues Mol Biol. 2023; 45(4):3391-3405. PMC: 10136867. DOI: 10.3390/cimb45040222. View

Magee J, Piskounova E, Morrison S . Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21(3):283-96. PMC: 4504432. DOI: 10.1016/j.ccr.2012.03.003. View

Xie R, Kessler T, Grosch J, Hai L, Venkataramani V, Huang L . Tumor cell network integration in glioma represents a stemness feature. Neuro Oncol. 2020; 23(5):757-769. PMC: 8099480. DOI: 10.1093/neuonc/noaa275. View

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. DOI: 10.1038/nature10833. View

Alcantara Llaguno S, Wang Z, Sun D, Chen J, Xu J, Kim E . Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. Cancer Cell. 2015; 28(4):429-440. PMC: 4607935. DOI: 10.1016/j.ccell.2015.09.007. View

Eastman A, Chen X, Hu X, Hartman A, Pearlman Morales A, Yang C . Resolving Cell Cycle Speed in One Snapshot with a Live-Cell Fluorescent Reporter. Cell Rep. 2020; 31(12):107804. PMC: 7418154. DOI: 10.1016/j.celrep.2020.107804. View

10.

Bhaduri A, Di Lullo E, Jung D, Muller S, Crouch E, Espinosa C . Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma. Cell Stem Cell. 2020; 26(1):48-63.e6. PMC: 7029801. DOI: 10.1016/j.stem.2019.11.015. View

11.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

12.

Couturier C, Ayyadhury S, Le P, Nadaf J, Monlong J, Riva G . Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun. 2020; 11(1):3406. PMC: 7343844. DOI: 10.1038/s41467-020-17186-5. View

13.

Snuderl M, Fazlollahi L, Le L, Nitta M, Zhelyazkova B, Davidson C . Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-7. DOI: 10.1016/j.ccr.2011.11.005. View

14.

Quintana E, Shackleton M, Sabel M, Fullen D, Johnson T, Morrison S . Efficient tumour formation by single human melanoma cells. Nature. 2008; 456(7222):593-8. PMC: 2597380. DOI: 10.1038/nature07567. View

15.

Bayliss J, Mukherjee P, Lu C, Jain S, Chung C, Martinez D . Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med. 2016; 8(366):366ra161. PMC: 5123566. DOI: 10.1126/scitranslmed.aah6904. View

16.

Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K . Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. J Pathol. 2014; 234(1):23-33. DOI: 10.1002/path.4366. View

17.

Ozawa T, Riester M, Cheng Y, Huse J, Squatrito M, Helmy K . Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014; 26(2):288-300. PMC: 4143139. DOI: 10.1016/j.ccr.2014.06.005. View

18.

Garofano L, Migliozzi S, Oh Y, DAngelo F, Najac R, Ko A . Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021; 2(2):141-156. PMC: 7935068. DOI: 10.1038/s43018-020-00159-4. View

19.

Feng J, Yao Z, Yang H, Ma J, Zhong X, Qin Y . Bone marrow-derived mesenchymal stem cells expressing BMP2 suppress glioma stem cell growth and stemness through Bcl-2/Bax signaling. J Cancer Res Ther. 2023; 18(7):2033-2040. DOI: 10.4103/jcrt.jcrt_1983_21. View

20.

Hubert C, Lathia J . Seeing the GBM diversity spectrum. Nat Cancer. 2022; 2(2):135-137. DOI: 10.1038/s43018-021-00176-x. View